We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA gave a thumbs up Monday to BioThrax to prevent anthrax following suspected or confirmed exposure in conjunction with recommended antibiotic treatment. Read More
An international aid group has negotiated a multi-year licensing agreement with Bristol-Myers Squibb to produce generic hepatitis C medicines in many developing nations. Read More
The U.S. Treasury Department says it is taking steps to curb tax-avoiding inversion deals, but there is little evidence to suggest it will halt the tie-up between New York-based Pfizer and Allergan that will see the former move its headquarters to Dublin. Read More
Drugmakers engaging in anticompetitive practices don’t get a free pass simply because federal regulators failed to act, the Federal Trade Commission has asserted in a pending court case. Read More
Spotty, inconclusive data and potentially skewed, biased findings have raised FDA concerns about the efficacy of BioMarin Pharmaceutical’s Duchenne muscular dystrophy candidate drisapersen, which is scheduled to go before members of an agency advisory panel tomorrow. Read More
Horizon Pharma has withdrawn its roughly $1 billion unsolicited bid to acquire specialty pharmaceutical company Depomed after a California judge ruled that Horizon improperly used confidential information. Read More
Sanofi and AstraZeneca are touting an innovative, open model of collaboration that will see the direct exchange of 210,000 compounds between the two companies’ proprietary libraries. Read More
The FDA has given Takeda’s Ninlaro the green light of approval in combination with other therapies to treat multiple myeloma in the second-line setting. Read More
Week in Review will not be published on Nov. 28 in observance of the Thanksgiving Holiday. The next Week in Review will be published on Dec. 5. Read More